Document is current
Any future updates will be listed below
-
Authors
Azam, Aleena https://orcid.org/0009-0002-1833-5178
Kurbegovic, Sorel
Carlsen, Esben Andreas
Andersen, Thomas Lund
Larsen, Vibeke André
Law, Ian
Skjøth-Rasmussen, Jane
Kjaer, Andreas https://orcid.org/0000-0002-2706-5547
-
Funding
Funding for this research was provided by:
Lundbeck Foundation (Lundbeck Foundation)
Novo Nordisk Fonden (Novo Nordisk Fonden)
Innovationsfonden (Innovationsfonden)
Neuroendocrine Tumor Research Foundation (Neuroendocrine Tumor Research Foundation)
Kræftens Bekæmpelse (Kræftens Bekæmpelse)
Arvid Nilssons Fond (Arvid Nilssons Fond)
The Neye Foundation (The Neye Foundation)
The Sygeforsikringen Danmark (The Sygeforsikringen Danmark)
The Research Foundation of Rigshospitalet (The Research Foundation of Rigshospitalet)
The Danish National Research Foundation - PERSEMONE (The Danish National Research Foundation - PERSEMONE)
The Research Council of the Capital Region of Denmark (The Research Council of the Capital Region of Denmark)
The Danish Health Authority (The Danish Health Authority)
The John and Birthe Meyer Foundation (The John and Birthe Meyer Foundation)
Danmarks Frie Forskningsfond (Danmarks Frie Forskningsfond)
H2020 European Institute of Innovation and Technology (670261, 668532)
- License Information
-
More Information
Article History
Received: 21 June 2024
Accepted: 16 October 2024
First Online: 29 October 2024
Declarations
:
: The trial was performed in accordance with the Helsinki Declaration and Good Clinical Practice. The trial was approved by the following: the Danish Medicines Agency (2016-002417-21), the Scientific Ethics Committee (H-16035303), and the Danish Data Protection Agency (2012-58-0004). The study was registered on clinicaltrials.gov (NCT02945826). Written informed consent was obtained from all patients.
: Not applicable.
: AK is an inventor on a patent of the composition of matter used in the study and a co-founder of Curasight that seeks to commercialize uPAR-PET. The current study is an academic investigator-initiated trial. No other potential conflicts of interest relevant are to this article exist.
